Zhenxin Anshen formula ameliorates atopic der-matitis-like skin dysfunction in mice and regulation of transient receptor potential vanilloid 1 and transient receptor potential ankyrin 1 in Neural pathways.

Article

Author: Yiding, Zhao ; Huiyan, Chi ; Chun, Dong ; Chaoyi, Mao ; Xiaoning, Yan ; Shanshan, Jiang ; Yong, Liu

OBJECTIVETo investigate the efficacy of Zhenxin Anshen formula (, ZXAS) on atopic dermatitis (AD) by transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1) signalling pathway in mice and .METHODSAD-like lesions were induced by 1-chloro-2,4-dinitrobenzene (DNCB) to the shaved dorsal skin of BALB/c mice. BALB/c mice were divided into five groups: normal control, model control, cetirizine, low-, medium-, and high-dose of ZXAS. After ZXAS in-tervention, the skin lesions and blood samples were collected for hematoxylin and eosin-stained and measuring the concentrations of inflammatory cytokines. Immun-oglobulin E (IgE), interleukin (IL)-4, IL-5, IL-13, and thymic stromal lymphopoietin (TSLP) were de-tected by Enzyme-linked immunosorbent assay (ELISA). The spinal cords were collected for measuring the expression of gastrin-releasing peptide receptor (GRPR), TRPV1, and TRPA1 by using immunohistochemistry, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) analyses. In addition, 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, ELISA, and Western blotting were conducted for analysis of primary dorsal root ganglia (DRG) neurons .RESULTSZXAS treatment improved DNCB-induced AD-like lesions through reducing dermatitis score, number of scratching and epidermal thickness, accompanied by the de-creased IgE and Th2 inflammatory cytokines. ZXAS also supressed the mRNA and protein expression of GRPR, TRPV1, and TRPA1 in the spinal cord. The medicated sera of ZXAS decreased capsaicin-induced Ca influx and downregulated the expression of TRPV1, TRPA1, and phospholipase C in DRG neurons.CONCLUSIONSThe therapeutic effect of ZXAS on AD may be related to the regulation of TRPV1 and TRPA1 and inhibition of Ca2+ signals in neurons.

01 Mar 1999·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Experimental study on effect of yishen shengxue tablet in treating aplastic anemia].

Article

Author: Zhou, A ; Wang, T ; Yang, J

OBJECTIVETo study the mechanism of Yishen Shengxue Tablet (YSSXT) in treating aplastic anemia.METHODSObserving the effect of YSSXT on hematopoietic, immunologic, anti-infection and body resistance of model mice of aplastic anemia.RESULTSYSSXT had marked effect of promotion on recovering myleran injury induced reduction of colony forming unit-spleen (CFU-S), colony forming unit-culture (CFU-C), colony forming unit-erythrocyte (CFU-E), markedly promoting the peritoneal macrophage phagocytosis of normal mice, also markedly lower the mortality of Staphylococcus aureus inoculated mice, and elevate the anoxia resistant ability under normal pressure of anoxic mice, prolonging their survival time.CONCLUSIONUsing YSSXT to treat aplastic anemia that the effectiveness might be realized through promoting the proliferation of hematopoietic stem cells of bone marrow, enhancing the non-specific immunity, and the anti-infection as well as body resistance.

01 Oct 1998·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical study on treatment of aplastic anemia mainly with Yishen Shengxue tablet].

Article

Author: Zhou, A ; Wang, T ; Yang, J

OBJECTIVETo assess the clinical effects of Yishen Shengxue tablet (YSSXT) on aplastic anemia.METHODSAll patients were divided into two groups by simple randomized methods, 106 patients of the treatment group were treated with YSSXT, 36 patients of the control groups were treated with Renshen Guipi Pill (RSGPP). Peripheral blood and bone marrow of the two groups of patients were measured before and after treatment. The toxicity and side effects of YSSXT were also observed.RESULTSThe basical cure rate, remission rate, total effective rate of the treatment and control groups were 23.6%, 36.8%, 82.1% and 11.1%, 22.2%, 58.3% respectively. There was significant difference between the two groups (P < 0.05 and P < 0.001). The effect of treatment group was obviously better than that of control group. Follow up study showed that from onset of the disease to follow up time in the treatment group, the longest one was 18 years 4 months, so the long-term curative effect is promising. During the period of clinical observation, no obvious side effect and toxicity of YSSXT were found.CONCLUSIONYSSXT is an effective and safe drug in treating aplastic anemia. It has a good prospect and application.

100 Deals associated with Yishen Yangxin Anshen Tablets

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	CN	Shijiazhuang Yiling Pharmaceutical Co., Ltd.	01 Sep 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Yishen Yangxin Anshen Tablets

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation